Orchid Chemicals & Pharmaceuticals

Orchid receives EU approvals for anti-bacterial injections Piperacillin, Tazobactam

04 Aug 2008

US FDA approval Orchid's ANDA for Cefpodoxime Proxetil

17 Nov 2007

Orchid's formulation and API facilities approved by UK MHRA

21 Sep 2006

Higher investments, rural affluence results in exponential corporate growth

23 Mar 2006

Orchid Chemicals' fire victims were insured: K Raghavendra Rao

08 Nov 2005

Orchid Chemicals strengthens finances with GDR and FCCB issue

31 Oct 2005

1: 2 bonus from Orchid Chemicals

18 Jul 2005

Orchid in deal with Stada for generic drug products

17 Mar 2005

Orchid in tie up with Par Pharmaceuticals Inc. to market oral cephalosporin in the US

28 May 2004

Orchid's US discovery JV successful

22 May 2004

View details about the software product Informachine News Trackers

Latest articles

Sigma Advanced to acquire UK aerospace supplier Bromford for ₹153 crore

 Sigma Advanced to acquire UK aerospace supplier Bromford for ₹153 crore

Akasa Air plans ₹1,050 crore fundraising to support growth amid higher costs

 Akasa Air plans ₹1,050 crore fundraising to support growth amid higher costs

AI startup Reflection signs over $1 billion computing deal with Nebius

 AI startup Reflection signs over $1 billion computing deal with Nebius

Tata Power explores $450 million overseas loan for business operations

 Tata Power explores $450 million overseas loan for business operations

TCS wins technology contract for New York JFK Airport’s $19 billion terminal

 TCS wins technology contract for New York JFK Airport’s $19 billion terminal

South Korean firms unveil $195 billion investment in AI and advanced industries

 South Korean firms unveil $195 billion investment in AI and advanced industries

HCLTech wins $1.14 billion AI transformation deal with European client

 HCLTech wins $1.14 billion AI transformation deal with European client

Microsoft launches Frontier to help enterprises accelerate AI adoption

 Microsoft launches Frontier to help enterprises accelerate AI adoption

AstraZeneca signs up to $1.77 billion CSPC deal for kidney disease drugs

 AstraZeneca signs up to $1.77 billion CSPC deal for kidney disease drugs